Clinical Trials Logo

Advanced or Metastatic NSCLC clinical trials

View clinical trials related to Advanced or Metastatic NSCLC.

Filter by:
  • None
  • Page 1

NCT ID: NCT05941897 Active, not recruiting - Clinical trials for Advanced or Metastatic NSCLC

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

LOTOS
Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

NCT ID: NCT05435248 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Start date: March 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.

NCT ID: NCT04942301 Not yet recruiting - Clinical trials for Advanced or Metastatic NSCLC

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This trial is an open-label, randomized, multicenter study to explore Endostar in combination with standard platinum-based chemotherapy with different methods in patients with advanced/metastatic non-small cell lung cancer (NSCLC)

NCT ID: NCT04612751 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

TROPION-Lung04
Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT04526691 Active, not recruiting - Clinical trials for Advanced or Metastatic NSCLC

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Start date: September 15, 2020
Phase: Phase 1
Study type: Interventional

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.

NCT ID: NCT04177290 Completed - Clinical trials for Advanced or Metastatic NSCLC

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Start date: April 2, 2020
Phase: Phase 1
Study type: Interventional

this is a phase I study comparing PK similarity of sintilimab by different production process (approved versus M1b) in Chinese advanced or metastatic NSCLC patients who have failed or been intolerant to at least one prior line of standard treatment

NCT ID: NCT03673332 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

EPITOP-01
Start date: August 9, 2019
Phase: Phase 4
Study type: Interventional

The co-primary objectives will be to assess the safety and quality of life under treatment.